17,261 trials
Leukemia, Myeloid, Acute · Acute Lymphoblastic Leukemia · Myelodysplasia
Primary: Cumulative Incidence of Patients With Engraftment by Day +30 Following Transplant — 88 percentage of participants
Basal Cell Carcinoma
Primary: Mean Percent Change From Baseline in the Number of Clinically Evident Basal Cell Carcinomas at Week 73 (After 72 Weeks of Treatment) — 62.9; 54.9 percent change
Acquired Antithrombin III Deficiency · Coronary Artery Bypass
Primary: Postoperative ATIII Levels at the ICU Admission — 94.06; 64.70 IU — p=<0.0001
Epithelial Ovarian Cancer
Primary: Progression-free Survival — 12.89; 8.64 Months
Prostate Adenocarcinoma · Stage I Prostate Cancer · Stage IIA Prostate Cancer
Primary: Tissue Levels of Calcitriol Between the Placebo and Cholecalciferol/Genistein Arms — 0.045; 0.057 ng/mL — p=0.922
Obesity
Primary: Assessment of % Excess Weight Loss — 45.4 %EWL
Diabetes · Infection
Primary: Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With…
Mitral Valve Insufficiency · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Mitral Regurgitation Severity — 0.0; 0.0; 5.6; 38.9 Percentage of participants
Psoriasis
Primary: Change in Target Lesion Scoring Evaluated at Baseline and 4 Weeks — -1.4; -1.4 units on a scale
Non-Squamous Non-Small Cell Lung Cancer
Primary: Number of Differentially Expressed Genes Associated With Clinical Benefit — 0 genes
Asthma
Primary: Change From Baseline in Asthma Control Questionnaire (ACQ) Score — -0.513; 0.001 score on a scale — p=0.005
Hypoglycemia
Primary: Time to Reach 50% of Maximum Glucose Concentration (Glucose T50%-Early) — 17.2; 21.9; 21.3; 7.6 minutes — p=0.23
Diabetic Macular Edema
Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…
Healthy Volunteers · Norovirus, Prevention
Primary: Percentage of Participants With a Seroresponse (Pan-Ig ELISA) — 43.3; 62.1; 46.4; 35.5 percentage of participants
Non Small Cell Lung Cancer · ROS1 Proto Oncogene · Crizotinib
Primary: Independent Radiology Reviewed Overall Objective Response (ORR) — 88 Participants